Detalles de la búsqueda
1.
Antibody-drug conjugate MORAb-202 exhibits long-lasting antitumor efficacy in TNBC PDx models.
Cancer Sci
; 112(6): 2467-2480, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-33756060
2.
Enhanced anti-angiogenic effect of E7820 in combination with erlotinib in epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small-cell lung cancer xenograft models.
Cancer Sci
; 105(8): 1023-31, 2014 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-24841832
3.
Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer.
Am J Pathol
; 181(3): 1034-43, 2012 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-22789825
4.
Antitumour activity of oral E7080, a novel inhibitor of multiple tyrosine kinases, in human sarcoma xenografts.
Int J Cancer
; 129(3): 742-50, 2011 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-21225632
5.
Folate receptor α increases chemotherapy resistance through stabilizing MDM2 in cooperation with PHB2 that is overcome by MORAb-202 in gastric cancer.
Clin Transl Med
; 11(6): e454, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-34185411
6.
E7386, a Selective Inhibitor of the Interaction between ß-Catenin and CBP, Exerts Antitumor Activity in Tumor Models with Activated Canonical Wnt Signaling.
Cancer Res
; 81(4): 1052-1062, 2021 02 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33408116
7.
Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase.
Clin Cancer Res
; 14(17): 5459-65, 2008 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-18765537
8.
E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition.
Int J Cancer
; 122(3): 664-71, 2008 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-17943726
9.
Broad-spectrum Preclinical Antitumor Activity of Eribulin (Halaven®): Combination with Anticancer Agents of Differing Mechanisms.
Anticancer Res
; 38(6): 3375-3385, 2018 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-29848686
10.
MORAb-202, an Antibody-Drug Conjugate Utilizing Humanized Anti-human FRα Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity.
Mol Cancer Ther
; 17(12): 2665-2675, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30262588
11.
Apratoxin A Shows Novel Pancreas-Targeting Activity through the Binding of Sec 61.
Mol Cancer Ther
; 15(6): 1208-16, 2016 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-27196783
12.
E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models.
Mol Cancer Ther
; 15(11): 2630-2639, 2016 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-27535969
13.
Antitumor activity of ER-37328, a novel carbazole topoisomerase II inhibitor.
Mol Cancer Ther
; 1(3): 169-75, 2002 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-12467211
14.
Small molecule schweinfurthins selectively inhibit cancer cell proliferation and mTOR/AKT signaling by interfering with trans-Golgi-network trafficking.
Cancer Biol Ther
; 16(4): 589-601, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25729885
15.
Pladienolides, new substances from culture of Streptomyces platensis Mer-11107. III. In vitro and in vivo antitumor activities.
J Antibiot (Tokyo)
; 57(3): 188-96, 2004 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-15152804
16.
Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma.
Mol Cancer Ther
; 13(4): 842-54, 2014 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-24563539
17.
Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer.
Clin Cancer Res
; 18(6): 1663-71, 2012 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-22317763
18.
Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
Mol Cancer Ther
; 11(10): 2149-57, 2012 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-22844075
19.
Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells.
Clin Cancer Res
; 18(13): 3592-602, 2012 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-22553343
20.
E7080 suppresses hematogenous multiple organ metastases of lung cancer cells with nonmutated epidermal growth factor receptor.
Mol Cancer Ther
; 10(7): 1218-28, 2011 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-21551260